Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
MIZUHO MEDY, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 55%, Dividend Revised Upward by 5 Yen
4595 MIZUHO MEDY CO.,LTD. 【J-GAAP】
Guidance Update ReportMIZUHO MEDY CO.,LTD. <4595> [TSE Std] announced a revision to its performance and dividend at noon (12:00) on December 19th. The ordinary profit (non-consolidated) forecast for the fiscal year ending December 2025 has been revised upward 55.4%, from the previous forecast of 3.03 billion yen to 4.72 billion yen (compared to 5.16 billion yen in the previous period), and the declining rate is expected to decrease from 41.2% to 8.6%.
Based on the upwardly revised full-year plan announced by the company, our calculation indicates that the July to December period (second half) ordinary profit is expected to increase 2.0 times, from the previous forecast of 1.64 billion yen to 3.32 billion yen (compared to 3.08 billion yen in the same period of the previous year), turning to a 7.7% increase in the ordinary profit outlook.
In light of the strong performance, the company has increased its planned annual dividend for the current fiscal year from the original plan of 95 yen to 100 yen.
Kabutan News
Guidance Update
Second Half Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Dec, 2025 Prev | 5,088 | 1,688 | 1,641 | 1,215 | 63.8 | 45 | Aug 8, 2025 | J-GAAP |
| Jul - Dec, 2025 New | 7,373 | 3,214 | 3,325 | 2,423 | 127.2 | 50 | Dec 19, 2025 | J-GAAP |
| Revision Rate | +44.9% | +90.4% | +102.6% | +99.4% | +99.5% |
Full Year Update
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2025 Prev | 9,064 | 3,164 | 3,038 | 2,235 | 117.3 | 95 | Aug 8, 2025 | J-GAAP |
| Dec, 2025 New | 11,349 | 4,690 | 4,722 | 3,443 | 180.8 | 100 | Dec 19, 2025 | J-GAAP |
| Revision Rate | +25.2% | +48.2% | +55.4% | +54.0% | +54.1% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Dec, 2024 | 6,761 | 3,074 | 3,086 | 2,284 | 119.9 | 60 | Feb 7, 2025 | J-GAAP |
| Jul - Dec, 2025 Guidance | 7,373 | 3,214 | 3,325 | 2,423 | 127.2 | 50 | Dec 19, 2025 | J-GAAP |
| YoY | +9.1% | +4.6% | +7.7% | +6.1% | +6.1% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2023 | 10,989 | 5,151 | 5,292 | 3,774 | 198.1 | 100 | Feb 9, 2024 | J-GAAP |
| Dec, 2024 | 11,429 | 4,917 | 5,167 | 3,773 | 198.1 | 100 | Feb 7, 2025 | J-GAAP |
| Dec, 2025 Guidance | 11,349 | 4,690 | 4,722 | 3,443 | 180.8 | 100 | Dec 19, 2025 | J-GAAP |
| YoY | -0.7% | -4.6% | -8.6% | -8.7% | -8.8% |
Related Articles
CAICA DIGITAL, 41% Increase in Ordinary Profit for The Current Fiscal Year
RIDE ON EXPRESS, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 62%
SATUDORA, First Half Ordinary Profit Decreases by 43%, Sep-Nov Ordinary Profit Decreases by 45%
OOMITSU, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 3% Decrease
CEL, Ordinary Profit Forecast for the Fiscal Year Revised Downward to an Unexpected 24% Decrease
Nikkei 225 open on the 19th = 386 yen higher, 49,387 yen
Tokyo Communications, Net Income Forecast for the Fiscal Year Revised Upward by 2.3 times
Nikkei 225 close on the 18th = falling, 510 yen lower to 49,001 yen
SecondXight Analytica, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 21%
Carna Biosciences, Net Income Forecast for the Fiscal Year Loss Widened in Downward Revision, 90% Deficit Against Net Assets